| Literature DB >> 21911546 |
Fang Yu1, Nathaniel W Nelson, Kay Savik, Jean F Wyman, Maurice Dysken, Ulf G Bronas.
Abstract
Aerobic exercise is a promising behavioral therapy for Alzheimer's disease (AD), yet few studies have investigated the effect of aerobic exercise on cognition in AD. The purpose of this pilot study was to examine the effect of 6-month aerobic exercise on the change in executive function, global cognition, quality of life (QOL), and depression in community-dwelling older adults with mild to moderate AD. A single group, repeated measures design with outcomes measured at baseline, 3 months, and 6 months was used. Results show that there were no significant changes in any measures except for depression (p = .026). There was a trend toward improvement in executive function and QOL with moderate effect sizes (ESs) and a trend toward deterioration in global cognition with moderate to large ESs. Randomized controlled trials are needed to evaluate the therapeutic effect of aerobic exercise in older adults with AD.Entities:
Mesh:
Year: 2011 PMID: 21911546 PMCID: PMC5696626 DOI: 10.1177/0193945911420174
Source DB: PubMed Journal: West J Nurs Res ISSN: 0193-9459 Impact factor: 1.967
Comparison of Outcome Measure Scores Over Time (n = 8)
| Outcome | Baseline | 3 Month | 6 Month | Friedman's Test | Effect Size | ||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| Variables/Measures | Chi-Square | Significance | Baseline to 6 Months | ||||
| Executive function | |||||||
| EXIT-25 | 13.3 ± 5.1, 7-21 | 1 1.6 ± 4.4, 5-18 | ll.6 ± 3.1, 8-16 | 0.75 | .69 | .48 | 37 |
| TMT Part A | 80.9 ± 32.1, 25-122 | 64.0 ± 21.8, 34-90 | 69.3 ± 37.7, 41-137 | 5.10 | .08 | .34 | 70 |
| TMT Part B | 253.4 ± 75.9, 112-300 | 257.4 ± 81.1, 95-300 | 254.1 ± 66.2, 134-300 | 0.93 | .63 | .02 | 19,625 |
| Stroop Word | 109.3 ± 7.4, 91-1 12 | 107.3 + 13.4, 74-112 | 107.3 + 13.0, 75-112 | 0.29 | .87 | .35 | 70 |
| Stroop Color-Word | 17.6+ 12.3, 3-42 | 28.0 ± 21.5, 3-75 | 20.1 ± 9.1, 6-29 | 3.80 | .15 | .27 | 110 |
| COWAT-FAS | 20.6 ± 7.7, 9-28 | 26.9 ± 8.8, 10-38 | 27.3 ± 12.1, 7-38 | 2.78 | .25 | .69 | 19 |
| F-words | 6.6 ± 3.2, 2-10 | 7.8 ± 2.9, 2-12 | 9.5 ± 5.4, 0-17 | 0.84 | .66 | .58 | 26 |
| A-words | 5.6 ± 3.2, 0-9 | 9.3 ± 3.8, 4-14 | 7.5 ± 4.5, 1-14 | 4.32 | .12 | .46 | 37 |
| S-words | 8.4 ± 2.3, 5-12 | 9.9 ± 3.5, 4-15 | 10.3 + 3.9, 4-15 | 2.87 | .24 | .63 | 22 |
| Global cognition | |||||||
| MMSE | 21.8 ± 5.1, 11-27 | 20.4 ± 6.6, 6-28 | 19.8 ± 6.0, 7-27 | 0.80 | .67 | .54 | 29 |
| ADAS-cog | 18.0 ± 7.7, 10-32 | 20.1 ± 9.9, 7-39 | 22.4 ± 9.3, 7-37 | 0.33 | .20 | 70 | 19 |
| QOL | |||||||
| QOL-AD | 42.6 ± 7.2, 31-52 | 44.6 ± 5.4, 38-52 | 43.4 ± 6.9, 33-52 | 0.90 | .64 | .31 | 84 |
| Depression | |||||||
| GDS-SF | 2.8 ± 4.3, 0-13 | 2.0 ± 1.9, 1-6 | 0.9 ± 1.7, 0-5 | 7.28 | .026 | .66 | 21 |
Note: EXIT-25: the Executive lnterview-25, score 0 to 50 with higher score indicating worse executive function; TMT: Trail Making Test, score 0 to 300 with higher score indicating worse executive function; Stroop Word and Color-Word Test: score each 0 to 112 with higher score indicating better executive function; COWA-FAS: Controlled Oral Word Association Test-Letters F, A, S, scores have no range with higher score indicating better executive function; MMSE: Mini-Mental State Examine, score 0 to 30 with higher score indicating better global cognition; ADAS-cog: Alzheimer's Disease Assessment Scale–Cognitive subscale, score 0 to 70 with higher score indicating worse global cognition; QOL-AD: Quality of Life in Alzheimer's Disease, score 13 to 52 with higher score indicating better quality of life; GDS-SF: Geriatric Depression Scale-Short Form, score 0 to 15 with higher score indicating more depression.
Effect sizes and required sample size for power of 80% were generated using the definition by Cohen.
The significance level is .05.